Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials
Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated incons...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1090533/full |
| _version_ | 1811158624389562368 |
|---|---|
| author | Patrick M. McCarthy Franklin A. Valdera Todd R. Smolinsky Alexandra M. Adams Anne E. O’Shea Katryna K. Thomas Spencer Van Decar Elizabeth L. Carpenter Ankur Tiwari John W. Myers Diane F. Hale Timothy J. Vreeland George E. Peoples Alex Stojadinovic Guy T. Clifton |
| author_facet | Patrick M. McCarthy Franklin A. Valdera Todd R. Smolinsky Alexandra M. Adams Anne E. O’Shea Katryna K. Thomas Spencer Van Decar Elizabeth L. Carpenter Ankur Tiwari John W. Myers Diane F. Hale Timothy J. Vreeland George E. Peoples Alex Stojadinovic Guy T. Clifton |
| author_sort | Patrick M. McCarthy |
| collection | DOAJ |
| description | Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated inconsistency in assessing the efficacy of cancer vaccination. Tumor infiltrating lymphocytes (TILs), reflect the local tumor microenvironment and may prove a superior endpoint in cancer vaccination trials. Cancer vaccines may also promote success in combination immunotherapy treatment of weakly immunogenic tumors. This review explores the impact of TILs as an endpoint for cancer vaccination in multiple malignancies, summarizes the current literature regarding TILs analysis, and discusses the challenges of providing validity and a standardized implementation of this approach. |
| first_indexed | 2024-04-10T05:27:17Z |
| format | Article |
| id | doaj.art-bc7c7eccb0dc43ea82221b1220d847ed |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T05:27:17Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-bc7c7eccb0dc43ea82221b1220d847ed2023-03-07T16:50:55ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.10905331090533Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trialsPatrick M. McCarthy0Franklin A. Valdera1Todd R. Smolinsky2Alexandra M. Adams3Anne E. O’Shea4Katryna K. Thomas5Spencer Van Decar6Elizabeth L. Carpenter7Ankur Tiwari8John W. Myers9Diane F. Hale10Timothy J. Vreeland11George E. Peoples12Alex Stojadinovic13Guy T. Clifton14Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, University of Texas Health Science Center, San Antonio, TX, United StatesDepartment of Surgery, Madigan Army Medical Center, Ft. Lewis, WA, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesCancer Insight, San Antonio, TX, United StatesCancer Insight, San Antonio, TX, United StatesDepartment of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United StatesCheckpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated inconsistency in assessing the efficacy of cancer vaccination. Tumor infiltrating lymphocytes (TILs), reflect the local tumor microenvironment and may prove a superior endpoint in cancer vaccination trials. Cancer vaccines may also promote success in combination immunotherapy treatment of weakly immunogenic tumors. This review explores the impact of TILs as an endpoint for cancer vaccination in multiple malignancies, summarizes the current literature regarding TILs analysis, and discusses the challenges of providing validity and a standardized implementation of this approach.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1090533/fulltumor infiltrating lymphocyte (TIL)cancer vaccinevaccinationendpointimmunotherapycheckpoint inhibition |
| spellingShingle | Patrick M. McCarthy Franklin A. Valdera Todd R. Smolinsky Alexandra M. Adams Anne E. O’Shea Katryna K. Thomas Spencer Van Decar Elizabeth L. Carpenter Ankur Tiwari John W. Myers Diane F. Hale Timothy J. Vreeland George E. Peoples Alex Stojadinovic Guy T. Clifton Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials Frontiers in Immunology tumor infiltrating lymphocyte (TIL) cancer vaccine vaccination endpoint immunotherapy checkpoint inhibition |
| title | Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials |
| title_full | Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials |
| title_fullStr | Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials |
| title_full_unstemmed | Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials |
| title_short | Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials |
| title_sort | tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials |
| topic | tumor infiltrating lymphocyte (TIL) cancer vaccine vaccination endpoint immunotherapy checkpoint inhibition |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1090533/full |
| work_keys_str_mv | AT patrickmmccarthy tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT franklinavaldera tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT toddrsmolinsky tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT alexandramadams tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT anneeoshea tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT katrynakthomas tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT spencervandecar tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT elizabethlcarpenter tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT ankurtiwari tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT johnwmyers tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT dianefhale tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT timothyjvreeland tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT georgeepeoples tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT alexstojadinovic tumorinfiltratinglymphocytesasanendpointincancervaccinetrials AT guytclifton tumorinfiltratinglymphocytesasanendpointincancervaccinetrials |